Identification

Name
Sacubitril
Accession Number
DB09292
Type
Small Molecule
Groups
Approved
Description

Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It was approved under the FDA's priority review process for use in heart failure on July 7, 2015.

Sacubitril's active metabolite, LBQ657 inhibits neprilysin, a neutral endopeptidase that would typically cleave natiuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP). ANP and BNP are released under atrial and ventricle stress, which activate downstream receptors leading to vasodilation, natriuresis and diuresis. Under normal conditions, neprilysin breaks down other vasodilating peptides and also vasoconstrictors such as angiotensin I and II, endothelin-1 and peptide amyloid beta-protein. Inhibition of neprilysin therefore leads to reduced breakdown and increased concentration of endogenous natriuretic peptides in addition to increased levels of vasoconstricting hormones such as angiotensin II.

Structure
Thumb
Synonyms
  • Sacubitril
  • Sacubitrilo
External IDs
AHU-377 / AHU377 / LCZ-696 / LCZ696
Active Moieties
NameKindUNIICASInChI Key
SacubitrilatprodrugSPI5PBF81S149709-44-4DOBNVUFHFMVMDB-BEFAXECRSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
EntrestoSacubitril (49 mg) + Valsartan (51 mg)Tablet, film coatedOralNovartis Europharm Limited2015-11-19Not applicableEu
EntrestoSacubitril (97 mg) + Valsartan (103 mg)Tablet, film coatedOralNovartis Europharm Limited2015-11-19Not applicableEu
EntrestoSacubitril (24 mg) + Valsartan (26 mg)Tablet, film coatedOralNovartis Europharm Limited2015-11-19Not applicableEu
EntrestoSacubitril (24 mg) + Valsartan (26 mg)TabletOralNovartis2015-11-13Not applicableCanada
EntrestoSacubitril (49 mg) + Valsartan (51 mg)Tablet, film coatedOralNovartis Europharm Limited2015-11-19Not applicableEu
EntrestoSacubitril (97 mg) + Valsartan (103 mg)TabletOralNovartis2015-11-13Not applicableCanada
EntrestoSacubitril (97 mg) + Valsartan (103 mg)Tablet, film coatedOralNovartis Europharm Limited2015-11-19Not applicableEu
EntrestoSacubitril (49 mg/1) + Valsartan (51 mg/1)Tablet, film coatedOralNovartis Pharmaceuticals Corporation2015-07-07Not applicableUs
EntrestoSacubitril (49 mg) + Valsartan (51 mg)Tablet, film coatedOralNovartis Europharm Limited2015-11-19Not applicableEu
EntrestoSacubitril (24 mg) + Valsartan (26 mg)Tablet, film coatedOralNovartis Europharm Limited2015-11-19Not applicableEu
Categories
UNII
17ERJ0MKGI
CAS number
149709-62-6
Weight
Average: 411.498
Monoisotopic: 411.204573038
Chemical Formula
C24H29NO5
InChI Key
PYNXFZCZUAOOQC-UTKZUKDTSA-N
InChI
InChI=1S/C24H29NO5/c1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19/h4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28)/t17-,21+/m1/s1
IUPAC Name
3-{[(2S,4R)-1-{[1,1'-biphenyl]-4-yl}-5-ethoxy-4-methyl-5-oxopentan-2-yl]carbamoyl}propanoic acid
SMILES
[H][C@@](CC1=CC=C(C=C1)C1=CC=CC=C1)(C[C@@]([H])(C)C(=O)OCC)NC(=O)CCC(O)=O

Pharmacology

Indication

Used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. It is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.

Associated Conditions
Pharmacodynamics

n a 7-day valsartan-controlled study in patients with reduced ejection fraction (HFrEF), administration of sacubitril + valsartan (Entresto) resulted in a significant non-sustained increase in natriuresis, increased urine cGMP, and decreased plasma MR-proANP and NT-proBNP compared to valsartan. In a 21-day study in HFrEF patients, it significantly increased urine ANP and cGMP and plasma cGMP, and decreased plasma NT-proBNP, aldosterone and endothelin-1. In clinical studies, this combination had no effect on QTc interval.

Mechanism of action

Sacubitril's active metabolite, LBQ657 inhibits neprilysin, a neutral endopeptidase that would typically cleave natiuretic peptides, which includes: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP). ANP and BNP are released under atrial and ventricle stress, which activate downstream receptors leading to vasodilation, natriuresis and diuresis. Under normal conditions, neprilysin breaks down other vasodilating peptides and also vasoconstrictors such as angiotensin I and II, endothelin-1 and peptide amyloid beta-protein. Therefore, the inhibition of neprilysin leads to reduced breakdown and increased concentration of endogenous natriuretic peptides in addition to increased levels of vasoconstricting hormones such as angiotensin II. (However, when combined with valsartan, would result in blocking of angiotensin II to its receptor, preventing the vasoconstrictive effects and resulting in a decrease in vascular resistance and blood pressure.) Cardiovascular and renal effects of sacubitril is a result of the increased levels of peptides that are normally degraded by neprilysin.

TargetActionsOrganism
ANeprilysin
antagonist
inhibitor
Human
Absorption

Peak plasma concentrations of sacubitril and it's metabolite, LBQ657 are reached in 0.5 hours and 2 hours respectively. Food does not clinically affect the systemic exposure of sacubitril or LBQ657. The oral bioavailability of sacubitril is >60%. It should be noted that the valsartan found in this combination is more bioavailable than other market available valsartan.

Volume of distribution

103 L

Protein binding

Sacubitril and it's metabolite, LBQ657 are highly bound to plasma protein (94-97%).

Metabolism

Sacubitril is metabolized to LBQ657 by esterases. A low concentration (<10%) of a hydroxyl metabolite has been identified in plasma.

Route of elimination

52% to 68% of sacubitril (primarily as the active metabolite LBQ657) is excreted in urine. 37% to 48% of sacubitril (primarily as LBQ657) is excreted in feces

Half life

The half life of sacubitril is 1.1 to 3.6 hours, and the half life of it's metabolite LBQ657 is 9.9 to 11.1 hours.

Clearance
Not Available
Toxicity

The most common adverse reactions (≥5%) are hypotension, hyperkalemia, cough, dizziness, and renal failure.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic AcidThe risk or severity of angioedema can be increased when 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid is combined with Sacubitril.
AbacavirAbacavir may decrease the excretion rate of Sacubitril which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Sacubitril which could result in a higher serum level.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Sacubitril.
AceclofenacAceclofenac may decrease the excretion rate of Sacubitril which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Sacubitril which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Sacubitril which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Sacubitril which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Sacubitril which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Food Interactions
No interactions found.

References

General References
  1. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP: Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010 Apr;50(4):401-14. doi: 10.1177/0091270009343932. Epub 2009 Nov 23. [PubMed:19934029]
  2. Mills J, Vardeny O: The Role of Neprilysin Inhibitors in Cardiovascular Disease. Curr Heart Fail Rep. 2015 Dec;12(6):389-94. doi: 10.1007/s11897-015-0270-8. [PubMed:26466607]
  3. King JB, Bress AP, Reese AD, Munger MA: Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review. Pharmacotherapy. 2015 Sep;35(9):823-37. doi: 10.1002/phar.1629. [PubMed:26406774]
External Links
KEGG Drug
D10225
PubChem Compound
9811834
PubChem Substance
310265184
ChemSpider
7987587
ChEBI
134714
ChEMBL
CHEMBL3137301
PharmGKB
PA166131580
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Sacubitril
ATC Codes
C09DX04 — Valsartan and sacubitril
FDA label
Download (1.28 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingBasic ScienceThyroid Cancer, Medullary1
1CompletedBasic ScienceMild and Moderate Renal Impairment1
2CompletedNot AvailableConcurrent Obesity / High Blood Pressure (Hypertension)1
2CompletedNot AvailableHepatic Impairment1
2CompletedNot AvailableMild to Moderate Hypertension1
2CompletedNot AvailableSalt-sensitive Hypertension1
2CompletedTreatmentChronic Heart Failure (CHF)1
2CompletedTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
2CompletedTreatmentHeart Failure, Unspecified1
2CompletedTreatmentHigh Blood Pressure (Hypertension)5
2CompletedTreatmentHypertension,Essential1
2CompletedTreatmentSystolic Hypertension1
2Not Yet RecruitingPreventionHeart Failure, Unspecified / Malignant Neoplasm of Female Breast1
2RecruitingTreatmentDiastolic Dysfunction1
2RecruitingTreatmentPeripheral Arterial Disease (PAD)1
2WithdrawnBasic ScienceHeart Failure, Unspecified1
2, 3RecruitingTreatmentPediatric Heart Failure1
3Active Not RecruitingTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF)1
3Active Not RecruitingTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
3CompletedTreatmentChronic Heart Failure With Reduced Ejection Fraction (HFrEF)2
3CompletedTreatmentHigh Blood Pressure (Hypertension)1
3CompletedTreatmentHypertension With Renal Dysfunction1
3CompletedTreatmentHypertension,Essential4
3CompletedTreatmentSevere Hypertension1
3Not Yet RecruitingTreatmentHeart Failure, Unspecified1
3Not Yet RecruitingTreatmentHypertensive Heart Disease1
3RecruitingOtherElevated Blood Pressure / High Blood Pressure (Hypertension) / Pre-Diabetic / Type 2 Diabetes Mellitus1
3RecruitingTreatmentAcute Myocardial Infarction (AMI)1
3RecruitingTreatmentChronic Heart Failure (CHF) / Heart Failure, Unspecified1
3RecruitingTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF)1
3TerminatedTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
3WithdrawnTreatmentHigh Blood Pressure (Hypertension)1
4CompletedOtherHeart Failure With Reduced Ejection Fraction (HFrEF)1
4CompletedSupportive CareAcute Heart Failure (AHF)1
4CompletedSupportive CareHeart Failure With Reduced Ejection Fraction (HFrEF)1
4CompletedSupportive CareHearth Failure With Reduced Ejection Fraction (HFrEF)1
4CompletedTreatmentMitral Valve Insufficiency / Symptomatic left ventricular ejection fraction ≤ 35% Chronic heart failure1
4Not Yet RecruitingBasic ScienceHigh Blood Pressure (Hypertension)1
4RecruitingOtherHeart Failure, Unspecified1
4RecruitingTreatmentBody Composition / Exercise Tolerance / Heart Failure, Unspecified / Strength, Muscle / Vasodilation1
4RecruitingTreatmentChronic Heart Failure With Reduced Ejection Fraction (HFrEF)1
4RecruitingTreatmentDiabetes Mellitus (DM) / Heart Failure, Unspecified1
4RecruitingTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF)1
4RecruitingTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
4RecruitingTreatmentHeart Failure, Systolic1
4RecruitingTreatmentHeart Failure, Unspecified5
4WithdrawnTreatmentCongestive Heart Failure (CHF) / High Blood Pressure (Hypertension)1
4WithdrawnTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF)1
Not AvailableActive Not RecruitingNot AvailableHeart Failure, Unspecified1
Not AvailableAvailableNot AvailableHeart Failure With Reduced Ejection Fraction (HFrEF)1
Not AvailableNot Yet RecruitingNot AvailableHeart Failure With Reduced Ejection Fraction (HFrEF)1
Not AvailableNot Yet RecruitingNot AvailableHeart Failure, Systolic1
Not AvailableRecruitingOtherChronic Heart Failure (CHF) / Sleep Apnea Syndrome1
Not AvailableRecruitingTreatmentCongestive Heart Failure (CHF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8796331No2014-08-052023-01-14Us
US8101659No2012-01-242023-01-14Us
US7468390No2008-12-232023-11-27Us
US8404744No2013-03-262023-01-14Us
US8877938No2014-11-042027-05-27Us
US9388134No2016-07-122026-11-08Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000942 mg/mLALOGPS
logP3.9ALOGPS
logP3.79ChemAxon
logS-5.6ALOGPS
pKa (Strongest Acidic)4.18ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.7 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity114.06 m3·mol-1ChemAxon
Polarizability45.41 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Gamma amino acids and derivatives / Amphetamines and derivatives / Fatty acid esters / N-acyl amines / Dicarboxylic acids and derivatives / Secondary carboxylic acid amides / Carboxylic acid esters / Carboxylic acids / Organopnictogen compounds / Organonitrogen compounds
show 3 more
Substituents
Biphenyl / Gamma amino acid or derivatives / Amphetamine or derivatives / Fatty acid ester / Dicarboxylic acid or derivatives / Fatty amide / N-acyl-amine / Fatty acyl / Carboxylic acid ester / Carboxamide group
show 12 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Inhibitor
General Function
Zinc ion binding
Specific Function
Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids (PubMed:15283675, PubMed:8168535). Biologically important in the destruction of opioid peptide...
Gene Name
MME
Uniprot ID
P08473
Uniprot Name
Neprilysin
Molecular Weight
85513.225 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Mills J, Vardeny O: The Role of Neprilysin Inhibitors in Cardiovascular Disease. Curr Heart Fail Rep. 2015 Dec;12(6):389-94. doi: 10.1007/s11897-015-0270-8. [PubMed:26466607]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Mills J, Vardeny O: The Role of Neprilysin Inhibitors in Cardiovascular Disease. Curr Heart Fail Rep. 2015 Dec;12(6):389-94. doi: 10.1007/s11897-015-0270-8. [PubMed:26466607]

Drug created on October 29, 2015 15:43 / Updated on December 16, 2018 06:56